Crossref

1. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection

- Ivan Gentile

- Antonio Riccardo Buonomo

- Guglielmo Borgia

2. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

- Ivan Gentile

- Nicola Coppola

- Antonio Riccardo Buonomo

- Emanuela Zappulo

- Guglielmo Borgia

3. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir

- Sean M. McConachie

- Sheila M. Wilhelm

- Pramodini B. Kale-Pradhan

4. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

- Ivan Gentile

- Antonio Riccardo Buonomo

- Federico Borgia

- Emanuela Zappulo

- Giuseppe Castaldo

- Guglielmo Borgia

5. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development

- Ivan Gentile

- Riccardo Scotto

- Emanuela Zappulo

- Antonio Riccardo Buonomo

- Biagio Pinchera

- Guglielmo Borgia

6. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C

- Nicola Coppola

- Ivan Gentile

- Giuseppe Pasquale

- Antonio Riccardo Buonomo

- Nicolina Capoluongo

- Maria D’Armiento

- Guglielmo Borgia

- Evangelista Sagnelli

7. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

- Ivan Gentile

- Alberto Enrico Maraolo

- Antonio Riccardo Buonomo

- Emanuela Zappulo

- Guglielmo Borgia

8. Understanding the Complexities of Cirrhosis

- Andrew J. Muir

9. Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients

- Tomas Koller

- Jana Kollerova

- Martin Huorka

- Iveta Meciarova

- Juraj Payer

10. Development and Validation of a Noninvasive Risk Score Model for Liver Cirrhosis in At-Risk Alcohol Drinkers Without HBV/HCV Infection

- Yin Liu

- Lan-Wei Guo

- Hui-Fang Xu

- Rui-Hua Kang

- Li-Yang Zheng

- Lu-Yao Zhang

- Qiong Chen

- Xi-Bin Sun

- You-Lin Qiao

- Shao-Kai Zhang

11. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?

- Ivan Gentile

- Antonio Riccardo Buonomo

- Emanuela Zappulo

- Guglielmo Borgia

12. Risk of Liver Cirrhosis in At-Risk Alcohol Drinkers Without HBV/HCV Infection: Development and Validation of a Simple Non-Invasive Risk Score Model

- Yin Liu

- Lan-wei Guo

- Hui-fang Xu

- Rui-hua Kang

- Li-yang Zheng

- Lu-yao Zhang

- Qiong Chen

- Xi-bin Sun

- Shao-kai Zhang

- You-Lin Qiao

13. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection

- Ivan Gentile

- Antonio Riccardo Buonomo

- Federico Borgia

- Giuseppe Castaldo

- Guglielmo Borgia

14. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis

- Jerzy Jaroszewicz

- Marta Flisiak-Jackiewicz

- Dariusz Lebensztejn

- Robert Flisiak

15. Beclabuvir for the treatment of hepatitis C

- Ivan Gentile

- Emanuela Zappulo

- Antonio Riccardo Buonomo

- Alberto Enrico Maraolo

- Guglielmo Borgia

16. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection

- Ivan Gentile

- Antonio Riccardo Buonomo

- Emanuela Zappulo

- Nicola Coppola

- Guglielmo Borgia

17. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus

- Ivan Gentile

- Emanuela Zappulo

- Antonio Riccardo Buonomo

- Guglielmo Borgia

18. Ferritin and liver fibrosis among patients with chronic hepatitis C virus infection

- Candelaria Martín-González

- Ricardo Pelazas-González

- Camino Fernández-Rodríguez

- Remedios Alemán-Valls

- Antonio Martínez-Riera

- Paula Ortega-Toledo

- Alen García-Rodríguez

- Melchor Rodríguez-Gaspar

- Emilio González-Reimers